KNSA - Total Utang marang Modal Kiniksa Corp

Logo perusahaan publik Kiniksa Pharmaceuticals (KNSA)

Kiniksa Pharmaceuticals (KNSA) relies on high-tech R&D centers while outsourcing drug manufacturing to third-party contractors. Increased sales of its primary pericarditis treatment have enabled the company to reach break-even and stop depleting its reserves. The price action reflects that the total debt-to-equity ratio is 0.01. This confirms the resilience of a business that monetizes patent protection and the exclusivity of therapies for rare inflammatory pathologies.

KNSA: Total Utang marang Modal Kiniksa 04.07.2022 - 31.10.2026

Rincian analitis perusahaan Kiniksa Pharmaceuticals

- rega lan prakiraan konsensus rega:
Bagan rega Kiniksa|KNSA - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Kiniksa|KNSA - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Kiniksa|KNSA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku kiniksa.com|KNSA - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Kiniksa Pharmaceuticals|KNSA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Kiniksa Pharmaceuticals|KNSA - Gunggung utang perusahaan|Utang marang nilai buku Kiniksa|KNSA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Kiniksa|Likuiditas cepet kiniksa.com
- informasi bathi lan kelipatan valuasi:
KNSA - Penghasilan resik
Analisis dhasar perusahaan:Kiniksa
Barang utama Kiniksa Corp

This indicator compares total liabilities to net assets, measuring the degree of financial leverage and the business's reliance on external borrowing. For Kiniksa Pharmaceuticals (KNSA), with its high margins in the orphan drug segment, the total debt-to-equity ratio demonstrates how effectively the company balances debt financing and the use of equity to strengthen its market position.

Analisis pesaing Kiniksa Pharmaceuticals

Utang marang Ekuitas argenx|BioNTech Inc. - Utang Agregat marang Ekuitas|Total Utang marang Modal ABVX|ADMA (ADMA Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PTGX (Protagonist Therapeutics)|Total Utang marang Modal immunovant.com IMVT|GRFS - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ADPT (Adaptive Biotech)|Celldex (CLDX) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Aurinia Corp|BCRX (BioCryst) - Total Utang marang Modal|Total Utang marang Modal veratx.com|Rasio Total Utang marang Ekuitas DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ABCL (abcellera.com)|Koefisien Total Utang marang Modal Tourmaline (TRML)|PGEN - Utang marang Ekuitas|pharming.com (PHAR) - Rasio Total Utang marang Ekuitas|Nektar Therapeutics Inc. (NKTR) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Upstream Bio, Inc.|Rasio Total Utang marang Ekuitas ZBIO|Total Utang marang Modal Immunome Bio|Utang marang Ekuitas Gossamer Bio, Inc. (GOSS)|kalvista.com - Rasio Utang marang Ekuitas|Total Utang marang Modal SEPN (Septerna)|Pieris Pharma (PVLA) - Utang marang Modal|SVRA - Utang marang Ekuitas|RIGL - Total Utang marang Modal|ANAB: Total Utang marang Modal|ATXS - Koefisien Total Utang marang Modal|Utang marang Ekuitas enGene|Rasio Utang marang Ekuitas RAPT (RAPT Therapeutics Inc.)|Total Utang marang Modal JBIO|Koefisien Total Utang marang Modal Aclaris Therapeutics, Inc|Utang marang Ekuitas Kyverna Therapeutics KYTX|Total Utang marang Modal tizianalifesciences.com TLSA|CABA - Utang marang Ekuitas|Koefisien Total Utang marang Modal Ventyx Biosciences Inc. VTYX|THTX: Total Utang marang Modal|Avalo Therapeutics Inc (AVTX) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas ELDN|AGEN: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Climb Bio (CLYM)|ZURA: Utang Agregat marang Ekuitas|Total Utang marang Modal ATYR (aTyr)|Rasio Kabeh Utang marang Dana Pribadi ADAG|Ikena Oncology, Inc. - Total Utang marang Modal|STTK - Total Utang marang Modal|equilliumbio.com (EQ) - Utang marang Ekuitas|Connect Biopharma Holdings Limited - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Immunic Therapeutics|Rasio Total Utang marang Ekuitas Atara Biotherapeutics Inc (ATRA)|Total Utang marang Modal IFRX|Total Utang marang Modal x4pharma.com (XFOR)|Total Utang marang Modal ACET (Adicet Bio, Inc.)|CELU - Rasio Total Utang marang Ekuitas|INmune Bio Corp - Total Utang marang Modal|Utang marang Modal Barinthus Biotherapeutics Corp|KZR (Kezar Life Sciences) - Rasio Total Utang marang Ekuitas|sabbiotherapeutics.com (SABS) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas AKTX|ENLV (Enlivex Therapeutics, Ltd.) - Utang Agregat marang Modal|Total Utang marang Modal QTTB|Koefisien Total Utang marang Modal GeoVax Corp|Total Utang marang Modal EDSA (Edesa Biotech, Inc.)|IBIO - Rasio Total Utang marang Ekuitas|Carisma Tx - Total Utang marang Modal|XTLB - Total Utang marang Modal|boltbio.com (BOLT) - Utang marang Ekuitas|HCWB (HCW Biologics) - Utang marang Ekuitas|Utang marang Ekuitas Aptevo Therapeutics, Inc.|AIM ImmunoTech, Inc. (AIM) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Aditxt (ADTX)|Total Utang marang Modal GRI Bio Inc (GRI)|Utang marang Ekuitas XORTX XRTX|HIND: Rasio Utang marang Ekuitas|REVB - Utang marang Ekuitas|Koefisien Total Utang marang Modal indaptusrx.com INDP|SCNI: Total Utang marang Modal|CalciMedica (CALI) - Total Utang marang Modal|Utang marang Ekuitas Affimed NV|Allakos Therapeutics - Utang Agregat marang Ekuitas|Total Utang marang Modal HOOK|IGMS (igmbio.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ITOS (iTeos Therapeutics, Inc.)|Total Utang marang Modal Ocean Biomedical Inc OCEA|TCBP - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi THRD (Third Harmonic Bio Inc)